All In Biotech

Drug Trial Radar · NCT04487236

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

61

Actual

Start

Oct 15, 2020

Primary completion

Apr 16, 2024

Study completion Apr 16, 2025

Sponsor

Lead sponsor
Suzhou Zanrong Pharma LimitedIndustry
Sponsor type
Industry
First posted
Jul 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors. The study will consist of three phases: phase 1a (dose escalation with ZN-A-1041 monotherapy), phase 1b (dose escalation with ZN-A-1041 in combination with Capecitabine and Trastuzumab) and phase 1c (dose expansion with ZN-A-1041 in combination with Capecitabine and Trastuzumab).

Conditions

  • Advanced Solid Tumors
  • HER2-positive Breast Cancer

Interventions

  • ZN-A-1041 50mg BIDDrug

    Orally 21days for one cycle

  • ZN-A-1041 100mg BIDDrug

    Orally 21days for one cycle

  • ZN-A-1041 200mg BIDDrug

    Orally 21days for one cycle

  • ZN-A-1041 400mg BIDDrug

    Orally 21days for one cycle

  • ZN-A-1041 600mg BIDDrug

    Orally 21days for one cycle

  • ZN-A-1041 800mg BIDDrug

    Orally 21days for one cycle

  • ZN-A-1041 1000mg BIDDrug

    Orally 21days for one cycle

  • ZN-A-1041 Level 1 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First CycleDrug

    ZN-A-1041 level 1 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

  • ZN-A-1041 Level 2 +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First CycleDrug

    ZN-A-1041 level 2 BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

  • ZN-A-1041 MAD +Capecitabine 1000 mg/m2 + Trastuzumab 8 mg/kg iv. First CycleDrug

    ZN-A-1041 MAD BID; Capecitabine 1000 mg/m2 BID Trastuzumab 8 mg/kg iv. First Cycle

  • ZN-A-1041+Capecitabine + Trastuzumab 8 mg/kg iv. First CycleDrug

    Base on 1b ZN-A-1041 dose Base on 1b Capecitabine dose Base on 1b Trastuzumab dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety/tolerability of ZN-A-1041 as a monotherapy on Phase 1aTime frame: 23days
  2. The safety/tolerability of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1bTime frame: 21days
  3. The safety of ZN-A-1041 in combination with Capecitabine and Trastuzumab in Phase 1cTime frame: through study completion, an average of 3 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer hospital Chinese academy of medical sciences

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.